Cellectis SA
PAR:ALCLS

Watchlist Manager
Cellectis SA Logo
Cellectis SA
PAR:ALCLS
Watchlist
Price: 4.035 EUR 0.5%
Market Cap: 290.9m EUR

Cellectis SA
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cellectis SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Cellectis SA
PAR:ALCLS
Revenue
$112.6m
CAGR 3-Years
45%
CAGR 5-Years
-3%
CAGR 10-Years
10%
Valneva SE
PAR:VLA
Revenue
€291.4m
CAGR 3-Years
-10%
CAGR 5-Years
19%
CAGR 10-Years
17%
Nanobiotix SA
PAR:NANO
Revenue
-€14m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Revenue
€13.6m
CAGR 3-Years
49%
CAGR 5-Years
18%
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Revenue
$3.8m
CAGR 3-Years
-27%
CAGR 5-Years
-30%
CAGR 10-Years
-3%
Eurobio Scientific SA
PAR:ALERS
Revenue
€162.1m
CAGR 3-Years
-2%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Cellectis SA
Glance View

Market Cap
291.8m EUR
Industry
Biotechnology

Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

ALCLS Intrinsic Value
2.473 EUR
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Cellectis SA's Revenue?
Revenue
112.6m USD

Based on the financial report for Sep 30, 2025, Cellectis SA's Revenue amounts to 112.6m USD.

What is Cellectis SA's Revenue growth rate?
Revenue CAGR 10Y
10%

Over the last year, the Revenue growth was 155%. The average annual Revenue growth rates for Cellectis SA have been 45% over the past three years , -3% over the past five years , and 10% over the past ten years .

Back to Top